Selected Grants
Lutetium Long-term Safety Follow-up study
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2035A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2024 - 2029Intermittent Fasting using a Fasting-Mimetic Diet to Improve Prostate Cancer Control and Metabolic Outcomes
ResearchCo Investigator · Awarded by Cedars Sinai Medical Center · 2023 - 2028PSMAddition: Lu-PSMA in mHSPC
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2022 - 2027Stellar-002: XL-092 +/- immunotherapy for genitourinary cancers
Clinical TrialPrincipal Investigator · Awarded by Exelixis, Inc · 2022 - 2027Improving outcomes of patients with advanced prostate cancer through a better understanding of provider decision-making
ResearchCollaborator · Awarded by National Cancer Institute · 2022 - 2027INC: Ipilimumab + Nivolumab + Ciforadenant in RCC
Clinical TrialPrincipal Investigator · Awarded by The University of Texas MD Anderson Cancer Center · 2023 - 2027Duke ACS Institutional Research Grant
ResearchSignificant Contributor · Awarded by American Cancer Society, Inc. · 2024 - 2026DoD: PCRP Clinical Consortium: Duke University Clinical Research Site
ResearchCo Investigator · Awarded by Department of Defense · 2007 - 2026Kidney Cancer Research Program Clinical Consortium Duke University Clinical Trial Site Award
ResearchPrincipal Investigator · Awarded by Department of Defense · 2024 - 2026Targeting Environmental Ferroptosis Protection as Novel Therapeutic Strategy for Metastatic Renal Cell Carcinoma
ResearchCo Investigator · Awarded by Department of Defense · 2023 - 2026Blocking glutamine utilization in advanced and therapy-resistant prostate cancer
ResearchCo-Mentor · Awarded by Department of Defense · 2024 - 2026A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metas
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2021 - 2026PSMAfore: Lu-PSMA for men with castrate-resistant prostate cancer
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2021 - 2026Outcomes Database to prospectivelY aSSEss changing therapY landscape in Renal Cell Carcinoma (ODYSSEY RCC)
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2020 - 2025ODYSSEY RCC
Clinical TrialPrincipal Investigator · Awarded by Exelixis, Inc · 2020 - 2025Trimodality Approach to Unfavorable Localized Prostate Cancer: a prospective trial of Neoadjuvant Pembrolizumab, ADT, and Prostate SBRT followed by Radical Prostatectomy
Clinical TrialPrincipal Investigator · Awarded by Merck & Co., Inc. · 2021 - 2025ODYSSEY RCC
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2020 - 2025Reducing prostate cancer aggressiveness via aptamer-mediated nuclear delivery of splice-switching oligonucleotides
ResearchInvestigator · Awarded by Johns Hopkins University · 2023 - 2025A Phase II open-label, Multicenter study of Apalutamide, Abiraterone Acetate and Prednisone in African American and Caucasian men with metastatic castrate-resistant prostate cancer
Clinical TrialPrincipal Investigator · Awarded by Janssen Pharmaceutica, Inc. · 2017 - 2025The Role of Implicit Bias on Outcomes of Patients with Advanced Solid Cancers
ResearchCo Investigator · Awarded by Mount Sinai School of Medicine · 2021 - 2025IRONMAN: ENHANCING SURVIVORSHIP IN MEN WITH ADVANCED PROSTATE CANCER
ResearchPrincipal Investigator · Awarded by Harvard T.H. Chan School of Public Health · 2023 - 2025Odyssey RCC
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2020 - 2024Kidney Cancer Research Program Clinical Consortium Duke University Clinical Trial Site
ResearchPrincipal Investigator · Awarded by Department of Defense · 2021 - 2024A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of PF-06940434 in Patients with Advanced or Metastatic Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2021 - 2024A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-resistant Prostate Cancer and DNA-Repair Anomalies
Clinical TrialPrincipal Investigator · Awarded by Janssen Pharmaceutica, Inc. · 2017 - 2024An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients with Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2020 - 2024Targeting glutamine utilization in therapy-resistant prostate cancer
ResearchCo-Mentor · Awarded by Department of Defense · 2021 - 2024A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Clinical TrialPrincipal Investigator · Awarded by Calithera Biosciences, Inc. · 2019 - 2024A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy
Clinical TrialPrincipal Investigator · Awarded by Blue Earth Diagnostics · 2020 - 2023Targeting RNA splicing in race-related aggressive and lethal prostate cancer
Clinical TrialCo Investigator · Awarded by Prostate Cancer Foundation · 2018 - 2023Therapeutic targeting of MESH1 in renal cell carcinoma
ResearchCo Investigator · Awarded by Department of Defense · 2020 - 2023Race-related germline genetic variation and response to secondary hormonal therapy in metastatic castration-resistant prostate cancer
ResearchPrincipal Investigator · Awarded by Department of Defense · 2019 - 2023Race-Related Alternative Splicing: Novel Targets in Prostate Cancer
ResearchCollaborator · Awarded by National Institutes of Health · 2017 - 2023Eisai Educational Program - December
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Eisai, Inc. · 2022 - 2022Therapeutic targeting of cystine addiction of renal cell carcinoma
ResearchCo Investigator · Awarded by Department of Defense · 2019 - 2022Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer
ResearchCollaborator · Awarded by Department of Defense · 2018 - 2022Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer
ResearchCollaborator · Awarded by Department of Defense · 2018 - 2022An IND-enabling Trial to Determine the Number and Volume of Injections Necessary for Adequate Distribution Throughout Cancer Metastases and to Validate Poliovirus Receptor (CD155) Expression in Prostate Cancer
ResearchCo Investigator · Awarded by V Foundation for Cancer Research · 2016 - 2022Decreasing the Financial Burden for Patients with Advanced Prostate Cancer By Understanding Provider Decision-Making
ResearchMentor · Awarded by American Urological Association Foundation · 2021 - 2022Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer
ResearchCo Investigator · Awarded by V Foundation for Cancer Research · 2016 - 2022Reducing prostate cancer aggressiveness via aptamer-mediated nuclear delivery of splice-switching oligonucleotides
ResearchInvestigator · Awarded by Department of Defense · 2020 - 2022Disparities in the Use of Oral Anticancer Agents in Kidney Cancer
ResearchCo Investigator · Awarded by Yale University · 2021 - 2021A Phase 1b/2 Study of Enzalutamide Plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC); Sponsor ¿ Memorial Sloan Kettering Cancer Center
Clinical TrialPrincipal Investigator · Awarded by The Prostate Cancer Clinical Trials Consortium · 2018 - 2021Advancing Cancer Care in the Rural Southeast: Delivering Novel Therapies In Our Community Cancer Centers
ResearchCo Investigator · Awarded by V Foundation for Cancer Research · 2019 - 2021ABI-RACE: A Phase II Open Label, Parallel group study of Abiraterone Acetate in African American and Caucasian Men with Metastic Castrate Resistant Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Janssen Pharmaceutica, Inc. · 2013 - 2021Disparities in the Use of Oral Anticancer Agents in Kidney Cancer
ResearchInvestigator · Awarded by National Institutes of Health · 2019 - 2020Validation and interrogation of differentially expressed and alternatively spliced genes in African American prostate cancer
ResearchCo Investigator · Awarded by Department of Defense · 2014 - 2020Prostate Cancer Outcomes: An International Registry
ResearchPrincipal Investigator · Awarded by Movember Foundation · 2016 - 2020Race-related differential splicing of the insulin receptor and prostate tumor cell biology
ResearchMentor · Awarded by National Institutes of Health · 2016 - 2020Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)
ResearchInvestigator · Awarded by Prostate Cancer Foundation · 2014 - 2020BMS Bladder and Prostate Practicum 2019
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2019 - 2019BAYER PROTOTYPE PROSTATE PROGRAM - 3 DAY PROGRAMMING
ConferencePrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2019 - 2019Bayer-Exini Radium-223 Retrospective Study
ResearchPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2016 - 2019A Phase I/II, Open-label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination with Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients with Advanced Cancer
Clinical TrialPrincipal Investigator · Awarded by Celldex Therapeutics, Inc. · 2015 - 2018Novel Immune Modulating Cellular Vaccine for Prostate Cancer Immunotherapy
ResearchCo Investigator · Awarded by Department of Defense · 2013 - 2017Aptamer Targeted Drug and Toxin Delivery to Prostate Cancer
FellowshipCollaborator · Awarded by Department of Defense · 2014 - 2016A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Clinical TrialPrincipal Investigator · Awarded by Exelixis, Inc · 2013 - 2016Using Aptamer Coated Nanoparticles Encapsulating Prostate Tumor Antigen Encoding mRNA to Target Dendritic Cells In Vivo
ResearchCo Investigator · Awarded by Department of Defense · 2012 - 2015Clinical Oncology Research Career Development Program
ResearchMentor · Awarded by National Institutes of Health · 2009 - 2015Alternative splicing and epithelial-mesenchymal plasticity in prostate tumors
ResearchCollaborating Investigator · Awarded by National Institutes of Health · 2008 - 2014PRACTICUM - SANOFI 3 DAY DISEASE STATE TRAINING PROGRAM (PROSTATE, STEM CELL TRANSPLANT,LEUKEMIA /LYMPHOMA)
ConferencePrincipal Investigator · Awarded by Sanofi US · 2014 - 2014Prostate Cancer, Stem Cell Transplantation and Leukemia/Lymphoma Practicum
ConferencePrincipal Investigator · Awarded by Sanofi US · 2014 - 2014CTSA UL
ResearchAdvisor · Awarded by National Institutes of Health · 2006 - 2012mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of Resistance
ResearchCo Investigator · Awarded by National Institutes of Health · 2007 - 2010External Relationships
- American Association for Cancer Research
- Astellas Pharma Inc.
- AstraZeneca Healthcare Foundation
- Bayer Healthcare Pharmaceuticals
- Eisai
- Exelixis, Inc.
- IDEOlogy Health
- Janssen AI (Johnson & Johnson)
- Mashup Media
- Merck
- Michael J Hennessey/OncLive
- Millenium Medical Publishing Inc
- Novartis pharmaceuticals
- Pfizer Inc.
- Sanofi Genzyme
- Up To Date Inc/Wolters Kluwer Health
- UroGPO
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.